Anti-programmed death receptor 1 blockade induces clinical response in a patient with metastatic collecting duct carcinoma

Abstract Collecting duct carcinoma (CDC) is a very rare subtype of renal cell carcinoma (RCC) accounting for

Saved in:
Bibliographic Details
Published in:Clinical genitourinary cancer 2016-08, Vol.14 (4), p.e431-e434
Main Authors: Rimar, Kalen J., MD, Meeks, Joshua J., MD/PhD, Kuzel, Timothy M., MD
Format: Article
Language:English
Subjects:
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - metabolism
Collecting duct carcinoma
Female
Hematology, Oncology and Palliative Medicine
Humans
Kidney Neoplasms - drug therapy
Kidney Neoplasms - metabolism
Metastatic renal cell carcinoma
Middle Aged
Nivolumab
Non–clear cell renal cell carcinoma
PD1 inhibitor
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Protein Kinase Inhibitors - therapeutic use
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Collecting duct carcinoma (CDC) is a very rare subtype of renal cell carcinoma (RCC) accounting for
ISSN:1558-7673
1938-0682
DOI:10.1016/j.clgc.2016.02.013